Karyopharm Therapeutics Falls As Pivotal Trial Hits Spleen Goal But Misses Symptom Mark

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) shares are down on Tuesday as the company reported mixed results from its Phase 3 SENTRY trial for myelofibrosis.